lung cancer
Conditions
Interventions
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily joined the study, signed an informed consent form; 2. Histopathological examination confirmed non-small cell lung cancer,EGFR mutation or ALK gene rearrangement was negative; 3. The subjects had not previously received systemic chemotherapy for advanced / metastatic NSCLC, chemotherapy and / or radiotherapy are allowed as part of neoadjuvant / adjuvant therapy; 4. Aged >=18 years old; 5. The researchers determined that patients could be treated with carrizumab combined with pemetrexed and platinum.
Exclusion criteria
Exclusion criteria: 1. Patients who also received other immune drugs or therapies; 2. Patients who are participating in other intervention studies; 3. Patients with other malignant tumors at the same time; 4. Pregnant or lactating women; 5. Any other situation in which the investigator considered that the patient was not suitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety (Incidence of AE >=3); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;progression-free survival rate;safety (Incidence of AE, SAE, RCCEP);correlation between typical AE and curative effect; | — |
Countries
China
Contacts
Public ContactDawei Chen
Shandong Institute of Cancer Prevention and Control
Outcome results
None listed